Results 1 to 10 of about 12,954,964 (236)

The use of 5-alpha reductase inhibitors in the treatment of benign prostatic hyperplasia. [PDF]

Asian J Urol, 2018
Benign prostatic hyperplasia (BPH) is characterized by an enlarged prostate, lower urinary tract symptoms (LUTS), and a decreased urinary flow rate. Common in older men, BPH is a progressive disease that can eventually lead to complications including ...
Kim EH, Brockman JA, Andriole GL.
europepmc   +4 more sources

Contraindicated use of 5-alpha-reductase inhibitors in women. [PDF]

Br J Clin Pharmacol, 2017
Item does not contain ...
Teichert M, van Puijenbroek E, Stricker BH.   +2 more
europepmc   +7 more sources

Diagnosis of prostate cancer with magnetic resonance imaging in men treated with 5-alpha-reductase inhibitors. [PDF]

World J Urol, 2023
Falagario UG, Lantz A, Jambor I, Busetto GM, Bettocchi C, Finati M, Ricapito A, Luzzago S, Ferro M, Musi G, Totaro A, Racioppi M, Carbonara U, Checcucci E, Manfredi M, D'Aietti D, Porcaro AB, Nordström T, Björnebo L, Oderda M, Soria F, Taimen P, Aronen HJ, Perez IM, Ettala O, Marchioni M, Simone G, Ferriero M, Brassetti A, Napolitano L, Carmignani L, Signorini C, Conti A, Ludovico G, Scarcia M, Trombetta C, Claps F, Traunero F, Montanari E, Boeri L, Maggi M, Del Giudice F, Bove P, Forte V, Ficarra V, Rossanese M, Mucciardi G, Pagliarulo V, Tafuri A, Mirone V, Schips L, Antonelli A, Gontero P, Cormio L, Sciarra A, Porpiglia F, Bassi P, Ditonno P, Boström PJ, Messina E, Panebianco V, De Cobelli O, Carrieri G, PROMOD Study Group.   +63 more
europepmc   +2 more sources

Use of 5-Alpha Reductase Inhibitors in Dermatology: A Narrative Review. [PDF]

Dermatol Ther (Heidelb), 2023
Escamilla-Cruz M, Magaña M, Escandón-Perez S, Bello-Chavolla OY.   +3 more
europepmc   +2 more sources

High Real-World Medication Adherence and Durable Clinical Benefit in Medicare Patients Treated with 5-Alpha Reductase Inhibitors for Benign Prostatic Hyperplasia. [PDF]

J Urol, 2020
Zhang H, Frendl DM, Wang Z, Olumi AF.
europepmc   +2 more sources

Effect of 5-Alpha Reductase Inhibitors on Magnetic Resonance Imaging and Prostate Cancer Detection. [PDF]

Biomolecules
Morote J, Picola N, Muñoz-Rodriguez J, Paesano N, Ruiz-Plazas X, Muñoz-Rivero MV, Celma A, Manuel GG, Miró B, Servian P, Abascal JM.   +10 more
europepmc   +2 more sources

Prostate Cancer Mortality and Use of 5-Alpha Reductase Inhibitors. [PDF]

World J Mens Health, 2020
Foldes CA, Wang R, Canfield SE.
europepmc   +5 more sources

The Use of 5-Alpha Reductase Inhibitors to Manage Benign Prostatic Hyperplasia and the Risk of All-cause Mortality. [PDF]

Urology, 2018
Wallner LP, DiBello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, Abell JE, D'Agostino R, Loo RK, Aaronson DS, Horwitz RI, Jacobsen SJ.   +11 more
europepmc   +2 more sources

The connection of 5-alpha reductase inhibitors to the development of depression

Biomedicine & Pharmacotherapy, 2021
Recent literature connects 5-alpha reductase inhibitors (5-ARIs) with neuropsychiatric adverse effects. Several clinical studies have indicated that former 5-ARIs users had a higher incidence of depressive symptoms and neuropsychiatric side effects than non-users.
Thiraphat, Saengmearnuparp, Bannakij, Lojanapiwat, Nipon, Chattipakorn, Siriporn, Chattipakorn   +3 more
openaire   +2 more sources

5-Alpha Reductase Inhibitors and the Risk of Prostate Cancer Mortality in Men Treated for Benign Prostatic Hyperplasia. [PDF]

Mayo Clin Proc, 2016
Wallner LP, DiBello JR, Li BH, Van Den Eeden SK, Weinmann S, Ritzwoller DP, Abell JE, D'Agostino R, Loo RK, Aaronson DS, Richert-Boe K, Horwitz RI, Jacobsen SJ.   +12 more
europepmc   +2 more sources